Literature DB >> 2121775

Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein.

C A Landis1, G Harsh, J Lyons, R L Davis, F McCormick, H R Bourne.   

Abstract

Activating mutations in the gene for the alpha-chain of Gs, the stimulatory regulator of adenylyl cyclase, have been identified in human GH-secreting pituitary tumors. Using the polymerase chain reaction and allele-specific oligonucleotide hybridization, we screened 25 GH-secreting tumors for the presence of the activating mutations. We also reviewed the clinical charts of the patients from whom the tumors were removed. Of 25 tumors, 10 (40%) contained activating mutations. Patients in the mutation-positive group came to surgery with smaller tumors and had lower GH levels. The activating mutations identify a subgroup of GH-secreting pituitary tumors that probably arise from a shared oncogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121775     DOI: 10.1210/jcem-71-6-1416

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  Mutations of signal-transducing G proteins in human disease.

Authors:  P Schnabel; M Böhm
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

3.  Distribution of Gs-alpha activating mutations in human thyroid tumors measured by subcloning.

Authors:  V N Gorelov; M Gyenes; F Neser; H D Röher; P E Goretzki
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 4.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

5.  Prkar1a haploinsufficiency ameliorates the growth hormone excess phenotype in Aip-deficient mice.

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Thomas Roetzer; Johannes A Hainfellner; Matthew F Starost; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

Review 6.  Somatostatin analogs in medical treatment of acromegaly.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 7.  Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system.

Authors:  Stuart J Frank; Serge Y Fuchs
Journal:  Biochim Biophys Acta       Date:  2008-06-09

8.  Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release.

Authors:  M L Hartman; S M Pincus; M L Johnson; D H Matthews; L M Faunt; M L Vance; M O Thorner; J D Veldhuis
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  A mutant alpha subunit of Gi2 induces neoplastic transformation of Rat-1 cells.

Authors:  A M Pace; Y H Wong; H R Bourne
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission.

Authors:  Pamela U Freda; Wendy K Chung; Naoki Matsuoka; Jane E Walsh; M Nabi Kanibir; George Kleinman; Yuanjia Wang; Jeffrey N Bruce; Kalmon D Post
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.